234 related articles for article (PubMed ID: 30967556)
1. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
Gröschel S; Hübschmann D; Raimondi F; Horak P; Warsow G; Fröhlich M; Klink B; Gieldon L; Hutter B; Kleinheinz K; Bonekamp D; Marschal O; Chudasama P; Mika J; Groth M; Uhrig S; Krämer S; Heining C; Heilig CE; Richter D; Reisinger E; Pfütze K; Eils R; Wolf S; von Kalle C; Brandts C; Scholl C; Weichert W; Richter S; Bauer S; Penzel R; Schröck E; Stenzinger A; Schlenk RF; Brors B; Russell RB; Glimm H; Schlesner M; Fröhling S
Nat Commun; 2019 Apr; 10(1):1635. PubMed ID: 30967556
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Pettitt SJ; Krastev DB; Brandsma I; Dréan A; Song F; Aleksandrov R; Harrell MI; Menon M; Brough R; Campbell J; Frankum J; Ranes M; Pemberton HN; Rafiq R; Fenwick K; Swain A; Guettler S; Lee JM; Swisher EM; Stoynov S; Yusa K; Ashworth A; Lord CJ
Nat Commun; 2018 May; 9(1):1849. PubMed ID: 29748565
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
5. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
6. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.
Ghiringhelli F; Richard C; Chevrier S; Végran F; Boidot R
World J Gastroenterol; 2016 Dec; 22(48):10680-10686. PubMed ID: 28082821
[TBL] [Abstract][Full Text] [Related]
7. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
[TBL] [Abstract][Full Text] [Related]
8. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
10. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
11. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
Reilly NM; Yard BD; Pittman DL
Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
[TBL] [Abstract][Full Text] [Related]
12. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
13. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
14. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
Jiang Y; Yam JC; Chu WK
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
[TBL] [Abstract][Full Text] [Related]
15. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
Ferrarotto R; Cardnell R; Su S; Diao L; Eterovic AK; Prieto V; Morrisson WH; Wang J; Kies MS; Glisson BS; Byers LA; Bell D
Head Neck; 2018 Aug; 40(8):1676-1684. PubMed ID: 29570891
[TBL] [Abstract][Full Text] [Related]
16. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
17. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
18. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
19. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.
Piombino C; Pipitone S; Tonni E; Mastrodomenico L; Oltrecolli M; Tchawa C; Matranga R; Roccabruna S; D'Agostino E; Pirola M; Bacchelli F; Baldessari C; Baschieri MC; Dominici M; Sabbatini R; Vitale MG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731844
[TBL] [Abstract][Full Text] [Related]
20. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]